Evaluation of effectiveness of palliative radiotherapy for bone metastases: a prospective cohort study

Abstract

ObjectiveRadiotherapy is the standard local treatment for patients with painful bone metastases, but effectiveness has primarily been evaluated in trial populations. The aim of this study was to study pain response to palliative radiotherapy in a prospective cohort of unselected patients with bone metastases.MethodsPatients with painful bone metastases referred to the UMC Utrecht for radiotherapy and enrolled in the PRESENT cohort were included in this study. For all patients, pain response to radiotherapy was assessed, and responders were defined as patients with a complete or partial pain response. Patients with stable pain scores, pain increase, or undetermined response were regarded non-responders. Pain scores obtained at baseline and after 2, 4, 6, 8, and 12 weeks following radiotherapy were obtained. Pain response rates of the total treated population, as well as response rates of the assessable patients, were calculated. To measure the percentage of the remaining time spent with pain relief, the net pain relief (NPR) was calculated by dividing the period of pain relief by the period of survival.ResultsOf the 432 patients enrolled in this study, 262 patients (61%) experienced a complete or partial response. In the 390 assessable patients, this percentage was 67%. Median time to response was 4 weeks (range 1–15 weeks), and the NPR was 64%.ConclusionCompared to randomized trial populations, palliative radiotherapy in our unselected patients with bone metastases showed similar pain response rates (61%), with a reasonable duration of this effect.

The efficacy of three-dimensional conformal radiation therapy on pain and quality of life in patients with painful bone metastases: a prospective study

“…The longer scheme is not always feasible in fragile palliative cancer patients who live far from the irradiation center, and we believe treatment schemes should be adapted to patients' clinical condition and life circumstances. Furthermore, in the study by van der Velden et al 61% patients achieved a complete or partial response ( 28 ), making their results very similar to ours.…”

Unexpected Response to Nivolumab in a “Fast Progressor” Head and Neck Cancer Patient

“…In the cases of oligo-metastases or metastases with slow progression or few numbers, local treatments such as radiotherapy may be more suitable, especially in the presence of symptoms. Indeed, radiotherapy provides excellent palliation for localized metastatic bone pain [5] and, even if no data available in this regard, the combination of immunotherapy with local treatments should be considered in order to achieve a better clinical benefit.…”

Patient-Reported Outcomes of Oligometastatic Patients After Conventional or Stereotactic Radiation Therapy to Bone Metastases: An Analysis of the PRESENT Cohort

“…The inclusion rate is about 90%. 18 This study was approved by the Institutional Review and Ethics Board of the Utrecht University and registered with clinicaltrials.gov (NCT02356497). Information on tumor and treatment characteristics, imaging, vital status, and PROs is prospectively collected.…”